AFMD - Affimed N.V.
After hours:
| Previous Close | 0.8734 |
| Open | 0.8754 |
| Bid | 0.8200 x 1300 |
| Ask | 0.8550 x 800 |
| Day's Range | 0.8211 - 0.9090 |
| 52 Week Range | 0.5500 - 3.4000 |
| Volume | |
| Avg. Volume | 760,109 |
| Market Cap | 123.608M |
| Beta (5Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.54 |
GlobeNewswireAffimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR mutant NSCLC; updated interim analysis data of 15 patients from the NSCLC cohort will be presented at ASCO on June 3, 2023AFM24-101 phase 1/2 interim results from the colorectal cancer (CRC) cohort show AFM24 was well tolerated in heavily pretreated patients with EGFR positive CRCCompany to host a c
ZacksAffimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -4.55% and 26.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL) and peripheral T Cell Lymphoma (PTCL). Affimed expects to initiate clinical trial in Q3 2023 and report initial data in H1 2024AFM24 monotherapy: Data from non-small cell lung cancer (NSCLC) expansion cohort accepted for poster presentation; data from colorectal cancer (CRC) cohort accepted for
- GlobeNewswire
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phasePrimary endpoints of the study are to assess the antitumor activity by objective response rate (ORR) including complete responses (CR) and partial responses (PR)Secondary endpoints of the study are to assess efficacy, durability of response (DOR), safety and tol
- GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
HEIDELBERG, Germany, May 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands. The notice and agenda of the An
- GlobeNewswire
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “W
- GlobeNewswire
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentationA trial in progress abstract of the phase 1 dose escalation study to assess safety and tolerability of AFM28 monotherapy in patients with r/r CD123-positive acute myeloid leukemia (AML) is accepted for online publication HEIDELBERG, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Compa
Simply Wall St.Affimed N.V.'s (NASDAQ:AFMD) Price Is Right But Growth Is Lacking
You may think that with a price-to-sales (or "P/S") ratio of 2.7x Affimed N.V. ( NASDAQ:AFMD ) is definitely a stock...
- GlobeNewswire
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentationAFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online publication HEIDELBERG, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with its innate cell engager (ICE®) AFM24 have been acc
- GlobeNewswire
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cellsIt demonstrates the potential of AFM13 to induce serial killing, even in tumor cells with low target expression HEIDELBERG, Germany, April 17, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster developed in collaboration with Prof.
- GlobeNewswire
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) populationPatients with Angioimmunoblastic T cell lymphoma (AITL), one of the most frequent subtypes of peripheral T Cell Lymphoma (PTCL), exhibited the highest ORR (53.3%) and CR (26.7%)Other measures of efficacy included median duration of response (DoR) of 2.3 months, median progression free survival (PFS) of 3.5 months and m
- GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 4, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common shares had closed below
- Simply Wall St.
Affimed N.V. (NASDAQ:AFMD) is a favorite amongst institutional investors who own 52%
Key Insights Institutions' substantial holdings in Affimed implies that they have significant influence over the...
- GlobeNewswire
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the first patient was dosed in a phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager (ICE®) AFM28 monotherapy in patients with CD123-positive relapsed/refractory (r/r) acute myeloid leukemia (AML). AFM28 efficiently directs natural kill
ZacksAffimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Affimed Reports 2022 Financial Results and Operational Progress
AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and SpainAnticipated cash runway into
- GlobeNewswire
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “
- GlobeNewswire
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)A poster presentation from the collaboration with Prof. Björn Önfelt at the KTH Royal Institute of Technology and Karolinska Institute in Stockholm with findings from the study investigating the impact of CD16A shedding on the potential to facilitate serial killing of tumor cells by AFM13-armed
GlobeNewswireAbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
PLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”. Under the grant, awarded to AbCheck by the Ministry of
- GlobeNewswire
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET. A live webcast of the fireside chat will be accessible on Affimed’s website at https://www.affimed.
- GlobeNewswire
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm. Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of
- GlobeNewswire
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET. A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/web
- GlobeNewswire
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinical study during 2023AFM24: Data updates from the three AFM24 ongoing studies are expected at scientific conferences in Q2/Q3 2023AFM28: Clinical trial application (CTA) cleared in France and Spain with additional filings in European countries pending; initiation of phase 1 study is expected in Q2 202
- Simply Wall St.
Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
- GlobeNewswire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to